Author

S. A. Moghadasi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 3 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Organism:non-human primate· 1 Organism:virus· 1

Frequent Co-Authors

R. Harris· 4 shared D. von Laer· 2 shared E. Heilmann· 2 shared F. Costacurta· 2 shared S. N. Moraes· 2 shared A. Auerbach· 1 shared A. Cheng· 1 shared A. Dodaro· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

R. Harris

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system

F. Costacurta, A. Dodaro, D. Bante, H. Schoeppe, B. Sprenger, S. A. Moghadasi, J. Fleischmann, M. Pavan, D. Bassani, S. Menin, S. Rauch, L. Krismer, A. Sauerwein, A. Heberle, T. Rabensteiner, , E. Heilmann

This study identifies and characterizes SARS-CoV-2 Mpro mutations conferring resistance to nirmatrelvir using a VSV-based system and biochemical assays.

bioRxiv · Sep 22, 2023Microbiology

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

S. A. Moghadasi, E. Heilmann, A. Khalil, C. Nnabuife, F. Kearns, C. Ye, S. N. Moraes, F. Costacurta, M. Esler, H. Aihara, D. von Laer, L. Martinez-Sobrido, T. Palzkill, R. E. Amaro, R. Harris

The paper identifies SARS-CoV-2 variants resistant to protease inhibitors nirmatrelvir and ensitrelvir, showing pre-existing resistance and potential for spread.

Science Advances · Mar 31, 2023Peer-reviewedMicrobiology

Rapid resistance profiling of SARS-CoV-2 protease inhibitors

S. A. Moghadasi, R. Biswas, D. A. Harki, R. Harris

The paper compares resistance profiles of nirmatrelvir, ensitrelvir, and FB2001 against SARS-CoV-2 Mpro variants using a cell-based assay, revealing distinct resistance mechanisms.

bioRxiv · Feb 25, 2023Microbiology

Evidence linking APOBEC3B genesis and evolution of innate immune antagonism by gamma-herpesvirus ribonucleotide reductases

S. N. Moraes, J. Becker, S. A. Moghadasi, N. Shaban, A. Auerbach, A. Cheng, R. Harris

The paper investigates how gamma-herpesvirus ribonucleotide reductases antagonize APOBEC3B, showing conservation across human and Old World monkey-infecting viruses but not New World monkey-infecting viruses.

bioRxiv · Apr 4, 2022Microbiology

Gain-of-function assay for SARS-CoV-2 Mpro inhibition in living cells

S. A. Moghadasi, J. T. Becker, C. Belica, C. Wick, W. L. Brown, R. Harris

The paper develops a gain-of-function assay to measure SARS-CoV-2 Mpro inhibition in living cells, using eGFP fluorescence to quantify inhibitor potency and enable high-throughput drug testing.

bioRxiv · Nov 9, 2020 · PreprintMicrobiology